サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
市場調査レポート
商品コード
1463715

北米の消費者直接遺伝子検査：2030年市場予測- 地域別分析- 検査タイプ、技術、流通チャネル別

North America Direct-to-Consumer Genetic Testing Market Forecast to 2030 - Regional Analysis - by Test Type, Technology, and Distribution Channel
出版日: | 発行: The Insight Partners | ページ情報: 英文 75 Pages | 納期: 即納可能 即納可能とは

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=157.14円
北米の消費者直接遺伝子検査：2030年市場予測- 地域別分析- 検査タイプ、技術、流通チャネル別
出版日: 2024年02月07日
発行: The Insight Partners
ページ情報: 英文 75 Pages
納期: 即納可能 即納可能とは
  • 全表示
  • 概要
  • 図表
  • 目次
概要

北米の消費者直接遺伝子検査市場は、2022年に7億1,640万米ドルと評価され、2030年には30億4,112万米ドルに達すると予測され、2022年から2030年までのCAGRは19.8%で成長すると推定されます。

遺伝性疾患の発生率の増加が北米の消費者直接遺伝子検査市場を後押し

遺伝性疾患の世界の負担は増加しています。ガーディアン紙が2022年に発表した記事によると、世界人口の～5％が鎌状赤血球症に罹患しており、世界では毎年約30万人の赤ちゃんが鎌状赤血球貧血で生まれています。世界保健機関は、1000人に10人が罹患していると推定しています。つまり、世界中で7,000万人から8,000万人がこれらの疾患のいずれかを抱えて生活していることになります。2020年、Online Mendelian Inheritance in Man（OMIM）リソースは、4,225の遺伝子からなる分子遺伝学的欠陥が知られている6,594の疾患をリストアップしました。この数は、OrphanetとOMIMのデータベースによれば、毎年約50-60の新しい遺伝性疾患に増加し続けています。NIH Undiagnosed Diseases Program and NetworkやInternational Rare Diseases Research Consortiumは、新規遺伝性疾患の発見率をさらに加速させているいくつかのイニシアチブです。

CDCによれば、アフリカ系アメリカ人の500人に1人が鎌状赤血球症と診断されており、常染色体劣性突然変異はアフリカ系アメリカ人の12人に1人が持っています。アルツハイマー協会によると、2023年までに65歳のアメリカ人の約670万人がアルツハイマー関連の認知症になるといいます。さらにその数は2060年までに1,380万人に増加すると予想されているが、この病気を遅らせたり治したりする画期的な方法は見つかっていないです。

新生児の遺伝性疾患の発生率も増加しています。世界保健機関（WHO）の2022年の報告書によると、神経管欠損、ダウン症、心臓欠損は、一般的な重度の先天性障害です。CDCによれば、米国では毎年6,000人近くの新生児がダウン症に罹患しており、これは700人に1人の割合です。インドでは毎年23,000人から29,000人近くの子供がダウン症に罹患しており、これは831人に1人の割合です。神経管欠損症」と題された報告書によると、ダウン症の種類と概要は以下の通りである：2021年にJournal of Family Medicine and Primary Care誌に掲載された"Different types and a brief overview of the neurulation process and its clinical implications "と題する報告書によると、世界では毎年30万例以上の神経管欠損症（NTD）が記録されています。これらの要因は、遺伝性疾患の遺伝子検査のイントロダクションを促しています。

したがって、世界の遺伝性疾患の発生率の増加が、消費者直接遺伝子検査市場の成長を後押ししています。

北米の消費者直接遺伝子検査市場概要

北米の消費者直接遺伝子検査市場は、米国、カナダ、メキシコに区分されます。北米は、遺伝性疾患の有病率の増加、研究開発への高い支出、米国食品医薬品局（FDA）による製品承認、技術の進歩により、大きな市場シェアを占めています。大規模ヘルスケア企業の存在とDtoC遺伝子検査の利用拡大が、2022-2030年の期間中、同地域における市場成長の機会を提供し続けると思われます。さらに、遺伝性疾患に対する懸念の高まりに対処するための政府からの支援の高まりは、北米における消費者直接遺伝子検査市場の進展に有利です。

北米の消費者直接遺伝子検査市場の収益と2030年までの予測（金額）

北米の消費者直接遺伝子検査市場セグメンテーション

北米の消費者直接遺伝子検査市場は、検査タイプ、技術、流通チャネル、国に区分されます。

検査タイプに基づき、北米の消費者直接遺伝子検査市場は、祖先検査、予測検査、ニュートリゲノミクス検査、キャリア検査、その他に区分されます。2022年には家系検査市場セグメントが最大のシェアを占めました。

技術面では、北米の消費者直接遺伝子検査市場は、全ゲノムシークエンシング、一塩基多型チップ、標的分析、その他に分類されます。一塩基多型チップセグメントは2022年に最大のシェアを占めました。

北米の消費者直接遺伝子検査市場は、販売チャネルに基づいてオンラインとオフラインに二分されます。オンラインセグメントが2022年に大きなシェアを占めました。

国別では、北米の消費者直接遺伝子検査市場は米国、カナダ、メキシコに区分されます。米国は2022年に北米の消費者直接遺伝子検査市場を独占しました。

Ancestry Genomics Inc、Color Health Inc、Helix Inc、Myriad Genetics, Inc、Living DNA Ltd、23andMe Inc、Genetic Technologies Ltd、Gene by Gene Ltd、Full Genomes Corp Incは、北米の消費者直接遺伝子検査市場で事業を展開している大手企業の一部です。

目次

目次

第1章 イントロダクション

第2章 エグゼクティブサマリー

  • 主要洞察

第3章 調査手法

  • 調査範囲
  • 2次調査
  • 1次調査

第4章 北米の消費者直接遺伝子検査市場情勢

  • PEST分析

第5章 北米の消費者直接遺伝子検査市場-主要産業力学

  • 市場促進要因
    • 遺伝性疾患の発生率の増加
    • 遺伝子検査の潜在的利益に関する意識の高まり
  • 市場抑制要因
    • 消費者直接遺伝子検査に関連する高コストとプライバシーの懸念
  • 市場機会
    • 一塩基多型（SNP）チップの採用拡大
  • 今後の動向
    • 薬理遺伝学への関心の高まりとテレヘルスの採用増加
  • 影響分析

第6章 消費者直接遺伝子検査市場-北米市場分析

  • 北米の消費者直接遺伝子検査市場売上高、2022年～2030年

第7章 北米の消費者直接遺伝子検査市場-2030年までの収益と予測：検査タイプ別

  • 北米の消費者直接遺伝子検査市場2022年・2030年検査タイプ別収益シェア（%）
  • 家系検査
  • ニュートリゲノミクス検査
  • 予測検査
  • キャリア検査
  • その他

第8章 北米の消費者直接遺伝子検査市場：収益と2030年までの予測：技術別

  • 北米の消費者直接遺伝子検査市場：2022年・2030年技術別売上高シェア（%）
  • 全ゲノムシーケンス
  • 一塩基多型チップ
  • ターゲット分析
  • その他

第9章 北米の消費者直接遺伝子検査市場：2030年までの収益と予測：流通チャネル別

  • 北米の消費者直接遺伝子検査市場：2022年および2030年の流通チャネル別売上高シェア（%）
  • オンラインプラットフォーム
  • オフラインプラットフォーム

第10章 北米の消費者直接遺伝子検査市場-2030年までの収益と予測-国別分析

  • 米国
  • カナダ
  • メキシコ

第11章 北米の消費者直接遺伝子検査市場-業界情勢

  • オーガニック開発
  • 無機的展開

第12章 企業プロファイル

  • Ancestry Genomics Inc
  • Color Health Inc
  • Helix Inc
  • Myriad Genetics, Inc.
  • Living DNA Ltd
  • 26andMe Inc
  • Genetic Technologies Ltd
  • Gene By Gene Ltd
  • Full Genomes Corp Inc

第13章 付録

図表

List Of Tables

  • Table 1. North America Direct-to-Consumer genetic testing market Segmentation
  • Table 2. US: North America Direct-to-Consumer Genetic Testing Market, by Test Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 3. US: North America Direct-to-Consumer Genetic Testing Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 4. US: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 5. Canada: North America Direct-to-Consumer Genetic Testing Market, by Test Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 6. Canada: North America Direct-to-Consumer Genetic Testing Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 7. Canada: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 8. Mexico: North America Direct-to-Consumer Genetic Testing Market, by Test Type - Revenue and Forecast to 2030 (US$ Million)
  • Table 9. Mexico: North America Direct-to-Consumer Genetic Testing Market, by Technology - Revenue and Forecast to 2030 (US$ Million)
  • Table 10. Mexico: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel - Revenue and Forecast to 2030 (US$ Million)
  • Table 11. Organic Developments Done by Companies
  • Table 12. Inorganic Developments Done by Companies
  • Table 13. Glossary of Terms, North America Direct-to-Consumer Genetic Testing Market

List Of Figures

  • Figure 1. North America Direct-to-Consumer genetic testing market Segmentation, By Country
  • Figure 2. PEST Analysis
  • Figure 3. North America Direct-to-Consumer Genetic Testing Market: Key Industry Dynamics
  • Figure 4. North America Direct-to-Consumer Genetic Testing Market: Impact Analysis of Drivers and Restraints
  • Figure 5. North America Direct-to-Consumer Genetic Testing Market Revenue (US$ Mn), 2020 - 2030
  • Figure 6. North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Test Type 2022 & 2030 (%)
  • Figure 7. Ancestry Testing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 8. Nutrigenomics Testing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 9. Predictive Testing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 10. Carrier Testing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 11. Others: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 12. North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Technology 2022 & 2030 (%)
  • Figure 13. Whole Genome Sequencing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 14. Single Nucleotide Polymorphism Chips: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 15. Targeted Analysis: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 16. Others: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 17. North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • Figure 18. Online Platform: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 19. Offline Platform: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 20. North America Direct-to-Consumer Genetic Testing Market, by Key Country - Revenue (2022) (US$ Million)
  • Figure 21. North America Direct-to-Consumer Genetic Testing Market, by Country, 2022 & 2030 (%)
  • Figure 22. US: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 23. Canada: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • Figure 24. Mexico: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
目次
Product Code: BMIRE00029622

The North America Direct-to-Consumer genetic testing market was valued at US$ 716.40 million in 2022 and is expected to reach US$ 3,041.12 million by 2030; it is estimated to grow at a CAGR of 19.8% from 2022 to 2030.

Growing Incidence of Genetic Disorders Fuels the North America Direct-to-Consumer Genetic Testing Market

The global burden of genetic diseases is increasing. According to an article published in 2022 by The Guardian, ~5% of the world's population is affected by sickle cell disease, and approximately 300,000 babies are born with sickle cell anemia worldwide every year. The World Health Organization estimates that 10 in 1,000 people are affected. This means 70 to 80 million people worldwide live with one of these diseases. In 2020, the Online Mendelian Inheritance in Man (OMIM) resource listed 6,594 diseases with known molecular genetic defects, comprising 4,225 genes. This number is continuously increasing to approximately 50-60 new genetic diseases annually, as per the Orphanet and OMIM databases. The NIH Undiagnosed Diseases Program and Network and the International Rare Diseases Research Consortium are a few initiatives further accelerating the discovery rate of novel genetic diseases.

According to the CDC, 1 in 500 African Americans are diagnosed with sickle cell disease, and the autosomal recessive mutation is carried by 1 in 12 African Americans. According to the Alzheimer's Association, by 2023, nearly 6.7 million Americans aged 65 will have Alzheimer's-related dementia. Furthermore, the number is expected to rise to 13.8 million by 2060, with no breakthrough that either slows or cures the disease.

The incidence of genetic disorders in newborns is also increasing. According to the World Health Organization 2022 report, neural tube defects, Down syndrome, and heart defects are a few common severe congenital disabilities. According to the CDC, in the US, Down syndrome affects nearly 6,000 newborn babies yearly, one in 700 babies; and in India, every year, nearly 23,000 to 29,000 children, one in 831, have Down syndrome. According to the report titled "Neural tube defects: Different types and a brief overview of the neurulation process and its clinical implications," published in the Journal of Family Medicine and Primary Care in 2021, more than 300,000 cases of Neural tube defects (NTDs) are recorded worldwide each year. These factors are encouraging the introduction of genetic testing for inherited diseases.

Therefore, the increasing incidence of genetic disorders worldwide boosts the Direct-to-Consumer genetic testing market growth.

North America Direct-to-Consumer Genetic Testing Market Overview

The North America Direct-to-Consumer genetic testing market is segmented into the US, Canada, and Mexico. North America accounts for a significant market share owing to the growing prevalence of genetic diseases, high spending on research and development, product approvals by the US Food and Drug Administration (FDA), and technological advances. The presence of large healthcare businesses and the growing usage of Direct-to-Consumer genetic testing would continue to offer opportunities for market growth in the region during the period 2022-2030. Further, rising support from governments to address growing concerns about genetic diseases favors the Direct-to-Consumer genetic testing market progress in North America.

North America Direct-to-Consumer Genetic Testing Market Revenue and Forecast to 2030 (US$ Million)

North America Direct-to-Consumer Genetic Testing Market Segmentation

The North America Direct-to-Consumer genetic testing market is segmented into test type, technology, distribution channel, and country.

Based on test type, the North America Direct-to-Consumer genetic testing market is segmented into ancestry testing, predictive testing, nutrigenomics testing, carrier testing, and others. The ancestry testing market segment held the largest share in 2022.

In terms of technology, the North America Direct-to-Consumer genetic testing market is categorized into whole genome sequencing, single nucleotide polymorphism chips, targeted analysis, and others. The single nucleotide polymorphism chips segment held the largest share in 2022.

Based on distribution channel, the North America Direct-to-Consumer genetic testing market is bifurcated into online and offline. The online segment held a larger share in 2022.

Based on country, the North America Direct-to-Consumer genetic testing market is segmented the US, Canada, and Mexico. The US dominated the North America Direct-to-Consumer genetic testing market in 2022.

Ancestry Genomics Inc, Color Health Inc, Helix Inc, Myriad Genetics, Inc., Living DNA Ltd, 23andMe Inc, Genetic Technologies Ltd, Gene by Gene Ltd, and Full Genomes Corp Inc are some of the leading companies operating in the North America Direct-to-Consumer genetic testing market.

Table Of Contents

Table of Content

1. Introduction

  • 1.1 The Insight Partners Research Report Guidance
  • 1.2 Market Segmentation

2. Executive Summary

  • 2.1 Key Insights

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. North America Direct-to-Consumer Genetic Testing Market Landscape

  • 4.1 Overview
  • 4.2 PEST Analysis

5. North America Direct-to-Consumer Genetic Testing Market - Key Industry Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Growing Incidence of Genetic Disorders
    • 5.1.2 Increasing Awareness About Potential Benefits of Genetic Testing
  • 5.2 Market Restraints
    • 5.2.1 High Cost and Privacy Concerns Associated With Direct-to-Consumer Genetic Testing
  • 5.3 Market Opportunities
    • 5.3.1 Growing Adoption of Single Nucleotide Polymorphism (SNP) Chips
  • 5.4 Future Trends
    • 5.4.1 Growing Interest in Pharmacogenetics and Increasing Adoption of Telehealth
  • 5.5 Impact Analysis

6. Direct-to-Consumer Genetic Testing Market - North America Market Analysis

  • 6.1 Overview
  • 6.2 North America Direct-to-Consumer Genetic Testing Market Revenue (US$ Mn), 2022 - 2030

7. North America Direct-to-Consumer genetic testing market - Revenue and Forecast to 2030 - by Test Type

  • 7.1 Overview
  • 7.2 North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Test Type 2022 & 2030 (%)
  • 7.3 Ancestry Testing
    • 7.3.1 Overview
    • 7.3.2 Ancestry Testing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.4 Nutrigenomics Testing
    • 7.4.1 Overview
    • 7.4.2 Nutrigenomics Testing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.5 Predictive Testing
    • 7.5.1 Overview
    • 7.5.2 Predictive Testing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.6 Carrier Testing
    • 7.6.1 Overview
    • 7.6.2 Carrier Testing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • 7.7 Others
    • 7.7.1 Overview
    • 7.7.2 Others: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)

8. North America Direct-to-Consumer genetic testing market - Revenue and Forecast to 2030 - by Technology

  • 8.1 Overview
  • 8.2 North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Technology 2022 & 2030 (%)
  • 8.3 Whole Genome Sequencing
    • 8.3.1 Overview
    • 8.3.2 Whole Genome Sequencing: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.4 Single Nucleotide Polymorphism Chips
    • 8.4.1 Overview
    • 8.4.2 Single Nucleotide Polymorphism Chips: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.5 Targeted Analysis
    • 8.5.1 Overview
    • 8.5.2 Targeted Analysis: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • 8.6 Others
    • 8.6.1 Overview
    • 8.6.2 Others: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)

9. North America Direct-to-Consumer genetic testing market - Revenue and Forecast to 2030 - by Distribution Channel

  • 9.1 Overview
  • 9.2 North America Direct-to-Consumer Genetic Testing Market Revenue Share, by Distribution Channel 2022 & 2030 (%)
  • 9.3 Online Platform
    • 9.3.1 Overview
    • 9.3.2 Online Platform: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
  • 9.4 Offline Platform
    • 9.4.1 Overview
    • 9.4.2 Offline Platform: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)

10. North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 - Country Analysis

  • 10.1 North America Direct-to-Consumer Genetic Testing Market, by Key Country- Revenue (2022) (US$ Mn)
    • 10.1.1 North America Direct-to-Consumer Genetic Testing Market, by Country, 2022 & 2030 (%)
      • 10.1.1.1 US: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (USD Million)
      • 10.1.1.2 US: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.2.1 US: North America Direct-to-Consumer Genetic Testing Market, by Test Type, 2020-2030 (US$ Million)
        • 10.1.1.2.2 US: North America Direct-to-Consumer Genetic Testing Market, by Technology, 2020-2030 (US$ Million)
        • 10.1.1.2.3 US: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 10.1.1.3 Canada: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (USD Million)
      • 10.1.1.4 Canada: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.4.1 Canada: North America Direct-to-Consumer Genetic Testing Market, by Test Type, 2020-2030 (US$ Million)
        • 10.1.1.4.2 Canada: North America Direct-to-Consumer Genetic Testing Market, by Technology, 2020-2030 (US$ Million)
        • 10.1.1.4.3 Canada: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel, 2020-2030 (US$ Million)
      • 10.1.1.5 Mexico: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (USD Million)
      • 10.1.1.6 Mexico: North America Direct-to-Consumer Genetic Testing Market - Revenue and Forecast to 2030 (US$ Million)
        • 10.1.1.6.1 Mexico: North America Direct-to-Consumer Genetic Testing Market, by Test Type, 2020-2030 (US$ Million)
        • 10.1.1.6.2 Mexico: North America Direct-to-Consumer Genetic Testing Market, by Technology, 2020-2030 (US$ Million)
        • 10.1.1.6.3 Mexico: North America Direct-to-Consumer Genetic Testing Market, by Distribution Channel, 2020-2030 (US$ Million)

11. North America Direct-to-Consumer Genetic Testing Market-Industry Landscape

  • 11.1 Overview
  • 11.2 Organic Developments
    • 11.2.1 Overview
  • 11.3 Inorganic Developments
    • 11.3.1 Overview

12. Company Profiles

  • 12.1 Ancestry Genomics Inc
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Color Health Inc
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Helix Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Myriad Genetics, Inc.
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Living DNA Ltd
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 26andMe Inc
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Genetic Technologies Ltd
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Gene By Gene Ltd
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 Full Genomes Corp Inc
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About Us
  • 13.2 Glossary of Terms